Mac Process and Schenck AccuRate To Merge and Be Renamed - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Mac Process and Schenck AccuRate To Merge and Be Renamed



Mac Process, a supplier of pneumatic conveying and air-filtration systems, and Schenck AccuRate, a leader in the manufacture and supply of dry material feeders and weighing technologies, have merged. Both companies are part of the global Schenck Process Group and have integrated their operations in North America under the name Schenck Process.

Manufacturing for Schenck Process will continue in Whitewater, WI and Sabetha, KS and the company headquarters will be located in Kansas City, MO. Integration efforts began in 2012, resulting in streamlined processes between the two operations, which provide pneumatic conveying, filtration, weighing, and feeding systems from one supplier.

Source: Mac Process

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here